文献速递肾小球疾病急性肾损伤

经颈静脉肾活检在抗血栓治疗的SLE和APS患者中的安全性与有效性

Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

结果显示接受抗血栓治疗的TJRB患者主要和次要并发症率与未治疗TCRB无显著差异,取样肾小球数量和诊断贡献相似,提示TJRB可用于出血风险高的SLE/APS患者。

要点

  • TJRB在抗血栓治疗的SLE/APS患者中并发症率与未治疗TCRB无显著差异。
  • 抗血栓治疗不影响TJRB的取样肾小球数量和诊断贡献。
  • 对出血风险高的SLE/APS患者,TJRB是可行的肾活检替代方案。

核心结论

  • 接受抗血栓治疗的SLE和APS患者行TJRB的诊断效能和安全性特征与未治疗TCRB相似。

研究设计与样本

  • 回顾性分析2004年1月至2016年10月单中心所有行肾活检的SLE和/或APS患者。

主要发现

  • 主要并发症率:未治疗TJRB 0%、阿司匹林组1%、抗凝组6%、TCRB组2%,四组无显著差异。
  • 次要并发症率:未治疗TJRB 8%、阿司匹林组6%、抗凝组10%、TCRB组2%,四组无显著差异。
  • 四组取样肾小球数量和活检对确立组织学诊断的贡献相似。

临床怎么用

  • 对于需抗血栓治疗的SLE和APS患者,可考虑采用TJRB以降低出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renal biopsy is the cornerstone of systemic lupus erythematosus (SLE) nephritis and antiphospholipid syndrome (APS) nephropathy management. However, transcutaneous renal biopsy (TCRB) is hampered by the antithrombotic treatment frequently prescribed for those diseases. Transjugular renal biopsy (TJRB) offers an attractive alternative for patients at increased risk of bleeding. The primary objective of the study was to describe the safety profile and diagnostic performance of TJRB in SLE and APS patients. METHODS: All SLE and/or APS patients who underwent a renal biopsy in our department (between January 2004 and October 2016) were retrospectively reviewed. Major complications were death, haemostasis nephrectomy, renal artery embolization, red blood cell transfusion, sepsis and vascular thrombosis; macroscopic haematuria, symptomatic perirenal/retroperitoneal bleeding and renal arteriovenous fistula without artery embolization were considered as minor complications. RESULTS: Two hundred and fifty-six TJRBs-119 without antithrombotics (untreated), 69 under aspirin and 68 on anticoagulants and 54 TCRBs without antithrombotics-were analysed. Their major and minor complication rates, respectively, did not differ significantly for the four groups: 0 and 8% for untreated TJRBs, 1 and 6% for aspirin-treated, 6 and 10% for anticoagulant-treated and 2 and 2% for TCRBs. The number of glomeruli sampled and the biopsy contribution to establishing a histological diagnosis was similar for the four groups. CONCLUSIONS: TJRBs obtained from SLE and APS patients taking antithrombotics had diagnostic yields and safety profiles similar to those of untreated TCRBs. Thus, TJRB should be considered for SLE and APS patients at risk of bleeding.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Nielly H, Mathian A, Cazenave M, et al. Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. Nephrol Dial Transplant. 2020. PMID: 31157889. doi:10.1093/ndt/gfz085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。